Dana-Farber Cancer Institute

https://www.dana-farber.org/

 

Genitourinary
25:33

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute Prostate Cancer Updates From ASCO GU 2023

FEATURING Jacob Berchuck, Atish Choudhury
  • 855 views
  • May 16, 2023
  • 7
04:50

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute Testicular Cancer Updates From ASCO GU 2023

FEATURING Alok Tewari
  • 48 views
  • May 16, 2023
20:18

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute Kidney Cancer Updates From ASCO GU 2023

FEATURING Wenxin Xu, Toni Choueiri
  • 241 views
  • May 16, 2023
19:48

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute Bladder Cancer Updates From ASCO GU 2023

FEATURING Charlene Mantia, Joaquim Bellmunt
  • 119 views
  • May 16, 2023
  • 1
15:35

Dana-Farber Cancer Institute

Updates on the Management of Non-Clear Cell RCC

FEATURING Bradley McGregor
  • 183 views
  • May 2, 2023
14:36

OncoAlert

RCC Updates: Perioperative Treatment, Metastatic ccRCC, and Non-Clear-Cell RCC

FEATURING Toni Choueiri
  • 370 views
  • March 1, 2023
14:01

ASCO GU 2023 Conference Coverage

ASCO GU 2023 Active Surveillance for Favorable Intermediate-Risk Prostate Cancer

FEATURING Anthony D'Amico
  • 117 views
  • February 22, 2023
51

Dana-Farber Cancer Institute

Lecture Summary - CARD Trial: Safety and Efficacy of Cabazitaxel in mCRPC & Age Subgroup Analysis

FEATURING Atish Choudhury
  • 4 views
  • July 28, 2022
09:06

Dana-Farber Cancer Institute

CARD Trial: Safety and Efficacy of Cabazitaxel in mCRPC & Age Subgroup Analysis

FEATURING Atish Choudhury
  • 71 views
  • July 28, 2022
03:13

Dana-Farber Cancer Institute

Outcomes of1L Ipi-Nivo & Subsequent Therapy in mRCC: Results From the International Database Consortium

FEATURING Andrew Schmidt
  • 9 views
  • June 11, 2021
25:49

Dana-Farber Cancer Institute

Beyond "The Big Three" Lynch Syndrome-Linked Cancers: What Are the Risk Factors? Should We Screen for the "Other" Cancers?

FEATURING Matthew Yurgelun
  • 4 views
  • January 28, 2021
13:19

Dana-Farber Cancer Institute

2020 ESMO IPATential150 Trial Data on mCRPC: Does Ipatasertib Combined With Abiraterone Acetate + Prednisone Lead to a Significantly Superior rPFS and Antitumor Activity in PTEN Loss Disease?

FEATURING Christopher Sweeney
  • 285 views
  • October 29, 2020
  • 1
26:17

Dana-Farber Cancer Institute

Current and Emerging Agents to Treat Advanced Bladder Cancer

FEATURING Guru Sonpavde
  • 812 views
  • March 5, 2019
  • 3
10:29

Dana-Farber Cancer Institute

Study of Atezolizumab and Bevacizumab in Variant Histology RCC: Data Support Evolving role of IO, PD-L1 Could be an IO Biomarker

FEATURING Bradley McGregor
  • 538 views
  • February 26, 2020
  • 1
08:37

Dana-Farber Cancer Institute

DFCI's ASCO 2019 Update: Review of FDA's Approval of the First Targeted Agent for Metastatic Urothelial Carcinoma - FGFRi Erdafitinib

FEATURING Guru Sonpavde
  • 1,649 views
  • June 24, 2019
  • 5
16:32

Dana-Farber Cancer Institute

DFCI's ASCO 2019 Update on Metastatic Urothelial Carcinoma: Analysis of Ongoing Clinical Trials - Enfortumab Vedotin Monotherapy, Gemcitabine/Cisplatin+Bevacizumab, Maintenance Pembrolizumab, and Coexpression Extrapolation (COXEN)

FEATURING Guru Sonpavde
  • 356 views
  • June 24, 2019
  • 1